Published on January 21, 2010 at 4:52 AM
pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leader in the
development of tiny, sustained-release drug delivery technologies, with
two of the only three ophthalmic sustained-release delivery products
approved by the FDA for treatment of back of the eye diseases, announced
that its chief executive officer, Dr. Paul Ashton, will discuss ocular
drug delivery in diabetic retinopathy during a presentation at the 6th
Annual Diabetes Conference in London, on Friday, January 22.
In his presentation Dr. Ashton will describe the barriers to clinically
effective therapies in diabetic retinopathy and the difficulty of
getting drugs to the back of the eye, where most diabetic eye disease
manifests itself. He is expected to discuss emerging drug delivery
technologies, including those under development at pSivida, which can
help to get drugs directly to the area of the eye where they can be most
effective in treating the underlying disease. As part of this
presentation, Dr. Ashton is also expected to recap recent top-line
results of the Phase 3 FAME™ trials of Iluvien® in patients with
diabetic macular edema that were reported last month by pSivida and its
licensee, Alimera Sciences.
Also scheduled to address the two-day conference are representatives
from GlaxoSmithKline, Sanofi-Aventis, Merck Sharp & Dohme, F.
Hoffman-LaRoche, AstraZeneca, Lilly, Astellas, Regeneron
Pharmacuegticals, Medpace and Fovea Pharmaceuticals, and leading
ophthalmologists from the University of Oxford and Moorfields Eye
Hospital.
SOURCE pSivida Corp.
105823ef-95c4-4851-bcbe-affc8a526f4d|0|.0
Posted in: Device / Technology News | Disease/Infection News
Tags: Biotechnology, Cancer, Cytomegalovirus, Diabetes, Diabetic Eye Disease, Diabetic Macular Edema, Diabetic Retinopathy, Drug Delivery, Edema, Exercise, Hospital, Pancreatic Cancer, Pfizer, Uveitis